MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2022: Top 25 Biotech Companies of 2022
Genmab A/S (NASDAQ: GMAB)
Organization & Developments: Genmab
Parents
Genmab A/S (NASDAQ: GMAB)
Children
*Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.
11. Genmab - 123.01M (€90.14M) 2010 R&D
2015: Investing In Johnson & Johnson's Pharmaceutical Collaborations Can Provide Dramatic Returns - Johnson & Johnson (NYSE:JNJ)
2020: AbbVie Plunks Down $750 Million Upfront for Cancer Therapy Deal with Genmab
2020: Genmab: An European R&D Behemoth With Long-Term Potential
2021: Genmab's Tisotumab Vedotin In Metastatic Cervical Cancer
2022: Genmab A/S 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Genmab: Darzalex Continues To Impress, Epcoritamab One Step Closer To Market_ seekingalpha.com
2022: Genmab: Great Company, But Stock Is Not That Great_ seekingalpha.com
2023: J&J, Genmab Unveil Darzalex Faspro Data with Eye Toward Earlier Multiple Myeloma Lines
2024: Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics
2024: Genmab buys 2nd anti-glycan antibody from Scancell, commits up to $630M in biobucks
2024: Genmab Is Too Attractive To Ignore
2024: Genmab shuffles C-Suite on commercialization, manufacturing as portfolio grows
2024: Genmab: 3 Trends To Track For A Strong 2024 And Beyond_ seekingalpha.com
2024: Genmab: Looking To Manage My Position Around Q3 Earnings
2024: Genmab: Recent Updates Support The Growth Narrative
2024: Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab_ seekingalpha
2024:Genmab A/S: Circling Back On This Complicated Story
2025: #8. Darzalex (daratumumab) Darzalex Faspro (daratumumab and hyaluronidase-fihj) Johnson & Johnson and Genmab3 2024 Sales: $11.670 billion3 2023 Sales: $9.744 billion3 % Change: +19.8%
2025: Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology
2025: Genmab: GEN3014's Demise And Implications For The HexaBody Platform_seekingalpha.com
2025: Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon_ seekingalpha.com
2025: J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data
Jumps
*Key People: Genmab
Finance & Acquisitions: Genmab